On September 30, Brown Rudnick hosted a stem cell event in Orange County, California.  The event was the first of Brown Rudnick's newly-launched Business Innovator Series, providing clients across the globe with the news, information and legal insights vital to their company’s growth and operations in today’s competitive landscape.

The event featured Randy Mills, the recently appointed President of the California Institute for Regenerative Medicine (CIRM). CIRM has awarded about $1.7 billion in grants to scientists at 65 institutions, including university medical schools and private companies.

From L to R: Ron Rus, Partner, Brown Rudnick; Art Torres, Vice-Chair, Governing Board of the CIRM; Randy Mills, President, CIRM; Numan Siddiqi, Partner, Brown Rudnick; Bill Lockyer, Counsel, Brown Rudnick

From L to R: Ron Rus, Partner, Brown Rudnick; Art Torres, Vice-Chair, Governing Board of the CIRM; Randy Mills, President, CIRM; Numan Siddiqi, Partner, Brown Rudnick; Bill Lockyer, Counsel, Brown Rudnick

From L to R: Rob Funsten, Partner Brown Rudnick; Art Torres, Vice-Chair, Governing Board of the CIRM; Ron Rus, Partner, Brown Rudnick; Jon Thomas, Chair, Governing Board of the CIRM

From L to R: Rob Funsten, Partner, Brown Rudnick; Art Torres, Vice-Chair, Governing Board of the CIRM; Ron Rus, Partner, Brown Rudnick; Jon Thomas, Chair, Governing Board of the CIRM 

 

About Randy Mills:

Prior to joining CIRM in May 2014, Mills was the former President and CEO of Osiris Therapeutics. Under Mills’ leadership Osiris developed the world’s first approved stem cell drug, remestemcel-L for graft versus host disease in children, a devastating complication of bone marrow transplantation that can be fatal. Mills, a member of the stem cell agency’s Grant Review Board for the past five years, was at Osiris for almost ten years before stepping down last December. Prior to that he served in several executive leadership roles with RTI Biologics Inc., and was a founding member of that company’s predecessor, the University of Florida Tissue Bank. He also served, at the appointment of the U.S. Secretary of Health and Human Services, as a voting member of the National Institutes of Health and AIDS Research Advisory Council and was vice chairman of the American Association of Tissue Bank’s Standards Committee. Mills has a bachelor’s degree in microbiology and cell science and a Ph.D. in drug development from the University of Florida.

About CIRM:

California's stem cell agency was created in 2004 when 59% of California voters approved Proposition 71: the California Stem Cell Research and Cures Initiative. That initiative created the California Institute for Regenerative Medicine (CIRM) to fund stem cell research in the state. In addition to creating the agency, Prop 71 created a 29-member governing board composed of researchers, business leaders and patient advocates. CIRM held its first meeting in December, 2004 to begin hiring a president, finding a headquarters, and establishing the three working groups to advise the board. The agency moved into headquarters in San Francisco in 2005 and issued the first round of funding in 2006. Since then, the agency has funded research and new facilities and has trained high school, undergraduate and graduate students for careers in stem cell science.

 

For more information on Brown Rudnick's Business Innovator Series, please click here.